440 related articles for article (PubMed ID: 27825137)
21. BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression.
Kim SH; Ryu H; Ock CY; Suh KJ; Lee JY; Kim JW; Lee JO; Kim JW; Kim YJ; Lee KW; Bang SM; Kim JH; Lee JS; Ahn JB; Kim KJ; Rha SY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30326563
[TBL] [Abstract][Full Text] [Related]
22. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
[TBL] [Abstract][Full Text] [Related]
23. HR+HER2- breast cancers with growth factor receptor-mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells.
Desai K; Aiyappa R; Prabhu JS; Nair MG; Lawrence PV; Korlimarla A; Ce A; Alexander A; Kaluve RS; Manjunath S; Correa M; Srinath BS; Patil S; Kalamdani A; Prasad M; Sridhar TS
Tumour Biol; 2017 Mar; 39(3):1010428317695028. PubMed ID: 28349782
[TBL] [Abstract][Full Text] [Related]
24. The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival.
Hu Y; Mintz A; Shah SR; Quinones-Hinojosa A; Hsu W
Carcinogenesis; 2014 Jul; 35(7):1491-9. PubMed ID: 24445144
[TBL] [Abstract][Full Text] [Related]
25. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
[TBL] [Abstract][Full Text] [Related]
26. Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.
Creedon H; Gómez-Cuadrado L; Tarnauskaitė Ž; Balla J; Canel M; MacLeod KG; Serrels B; Fraser C; Unciti-Broceta A; Tracey N; Le Bihan T; Klinowska T; Sims AH; Byron A; Brunton VG
Oncotarget; 2016 Mar; 7(10):11539-52. PubMed ID: 26883193
[TBL] [Abstract][Full Text] [Related]
27. A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.
Wu Y; Tran T; Dwabe S; Sarkissyan M; Kim J; Nava M; Clayton S; Pietras R; Farias-Eisner R; Vadgama JV
Breast Cancer Res Treat; 2017 Jun; 163(3):449-460. PubMed ID: 28337662
[TBL] [Abstract][Full Text] [Related]
28. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.
Wendt MK; Smith JA; Schiemann WP
Oncogene; 2010 Dec; 29(49):6485-98. PubMed ID: 20802523
[TBL] [Abstract][Full Text] [Related]
29. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
Terai H; Soejima K; Yasuda H; Nakayama S; Hamamoto J; Arai D; Ishioka K; Ohgino K; Ikemura S; Sato T; Yoda S; Satomi R; Naoki K; Betsuyaku T
Mol Cancer Res; 2013 Jul; 11(7):759-67. PubMed ID: 23536707
[TBL] [Abstract][Full Text] [Related]
30. LncRNA-ATB promotes trastuzumab resistance and invasion-metastasis cascade in breast cancer.
Shi SJ; Wang LJ; Yu B; Li YH; Jin Y; Bai XZ
Oncotarget; 2015 May; 6(13):11652-63. PubMed ID: 25871474
[TBL] [Abstract][Full Text] [Related]
31. Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer.
Peng R; Chen Y; Wei L; Li G; Feng D; Liu S; Jiang R; Zheng S; Chen Y
Gastric Cancer; 2020 Nov; 23(6):988-1002. PubMed ID: 32617693
[TBL] [Abstract][Full Text] [Related]
32. The Disintegrin and Metalloprotease ADAM12 Is Associated with TGF-β-Induced Epithelial to Mesenchymal Transition.
Ruff M; Leyme A; Le Cann F; Bonnier D; Le Seyec J; Chesnel F; Fattet L; Rimokh R; Baffet G; Théret N
PLoS One; 2015; 10(9):e0139179. PubMed ID: 26407179
[TBL] [Abstract][Full Text] [Related]
33. The relationship between EMT, CD44
Johansson AC; La Fleur L; Melissaridou S; Roberg K
J Oral Pathol Med; 2016 Oct; 45(9):640-646. PubMed ID: 26757432
[TBL] [Abstract][Full Text] [Related]
34. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
35. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
37. The proinflammatory LTB4/BLT1 signal axis confers resistance to TGF-β1-induced growth inhibition by targeting Smad3 linker region.
Jeon WK; Choi J; Park SJ; Jo EJ; Lee YK; Lim S; Kim JH; Letterio JJ; Liu F; Kim SJ; Kim BC
Oncotarget; 2015 Dec; 6(39):41650-66. PubMed ID: 26497676
[TBL] [Abstract][Full Text] [Related]
38. (-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
Siddique AB; Ebrahim HY; Akl MR; Ayoub NM; Goda AA; Mohyeldin MM; Nagumalli SK; Hananeh WM; Liu YY; Meyer SA; El Sayed KA
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30781364
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
[TBL] [Abstract][Full Text] [Related]
40. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
